BBOT Dips Close to Lows With One Cancer Drug Update Steering Trade
• BBOT was near $8.90 in early Nasdaq trading, down from Thursday’s close, and volume was thin.• U.S. equities were open on Friday; markets are shut Monday for Memorial Day.• Investors are waiting for new clinical data, expected in the second half of 2026. BridgeBio Oncology Therapeutics shares slipped early Friday, pausing after a recent bounce as traders waited for later-stage cancer drug results set for this year. BBOT last traded near $8.90, in a session range of $8.85 to $9.25. The Nasdaq Composite was up roughly 0.4%.